Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

US11427627B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Zhimei Du · Robinswood, US
• Pranhitha Reddy · Seattle, US
• Randal B. Bass · Seattle, US
• Feng HE · Lynnwood, US
• William C. Fanslow, III · Federal Way, US
• Yuling Zhang · Bellevue, US
• Da Ren · Thousand Oaks, US
• Randal R. Ketchem · Snohomish, US

Key dates

• Filing date: Sep 5, 2014
• Grant date: Aug 30, 2022
• Expiry date: Aug 27, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to variant Fc-containing molecules, such as antibodies and Fc-fusion molecules, having glycosylation characteristics favorable to largescale production of therapeutic molecules containing such variant Fc. Described herein are compositions and methods to improve glycosylation maturation of and to minimize the culture process-dependent effects of Fc-containing molecules, e.g., Fc-fusion molecules and antibodies. Creating single and multiple amino acid substitutions within the Fc domain with the aim to improve high mannose processing and glycosylation maturation.